<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436709</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000529855</org_study_id>
    <secondary_id>MSKCC-06019</secondary_id>
    <nct_id>NCT00436709</nct_id>
  </id_info>
  <brief_title>Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer</brief_title>
  <official_title>A Pilot Study of Bevacizumab With Dose Dense Doxorubicin and Cyclophosphamide (AC) Followed by Dose Dense Nanoparticle Albumin Bound Paclitaxel for the Treatment of Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the&#xD;
      growth of breast cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such&#xD;
      as doxorubicin, cyclophosphamide, and paclitaxel albumin-stabilized nanoparticle formulation,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving bevacizumab together with chemotherapy after surgery may&#xD;
      kill any tumor cells that remain after surgery.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the side effects and how well giving bevacizumab&#xD;
      together with doxorubicin and cyclophosphamide followed by paclitaxel albumin-stabilized&#xD;
      nanoparticle formulation and bevacizumab works in treating patients who have undergone&#xD;
      surgery for early-stage breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the cardiac safety of adjuvant concurrent bevacizumab and dose-dense&#xD;
           doxorubicin hydrochloride and cyclophosphamide followed by dose-dense paclitaxel&#xD;
           albumin-stabilized nanoparticle formulation and maintenance therapy comprising&#xD;
           bevacizumab alone in patients with early-stage breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the noncardiac toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the efficacy of this regimen, in terms of time to tumor recurrence and overall&#xD;
           survival, in these patients.&#xD;
&#xD;
        -  Explore changes in circulating endothelial cells and circulating tumor cells from&#xD;
           pre-treatment levels in patients with no evidence of disease.&#xD;
&#xD;
        -  Prospectively explore the use of serial troponin I as a predictor of cardiac toxicity in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Prospectively explore the relationship between plasma renin activity and hypertension in&#xD;
           patients treated with bevacizumab and chemotherapy.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, pilot, multicenter study.&#xD;
&#xD;
      Patients receive doxorubicin hydrochloride IV, cyclophophamide IV, and bevacizumab IV over&#xD;
      30-90 minutes on day 1 and pegfilgrastim subcutaneously (SC) on day 2. Treatment repeats&#xD;
      every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30&#xD;
      minutes on day 1 and pegfilgrastim SC on day 2. Treatment with paclitaxel albumin-stabilized&#xD;
      nanoparticle formulation and pegfilgrastim repeats every 2 weeks for 4 courses in the absence&#xD;
      of disease progression or unacceptable toxicity. Patients then receive maintenance therapy&#xD;
      comprising bevacizumab IV over 30-90 minutes on day 1. Treatment with maintenance therapy&#xD;
      repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Blood samples are collected at baseline and periodically during study treatment. Samples are&#xD;
      analyzed for circulating endothelial cells (by flow cytomery [FC]), circulating epithelial&#xD;
      cells (by immunocytochemistry and FC), troponin I concentrations (by enzyme immunoassay or&#xD;
      chemiluminescent microparticle immunoassay), and plasma renin activity (by radioimmunoassay).&#xD;
&#xD;
      After completion of study treatment, patients are followed every 4-6 months for 3 years,&#xD;
      every 6 months for 2 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 75 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2006</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Noncardiac toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor recurrence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel albumin-stabilized nanoparticle formulation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>immunoscintigraphy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed invasive breast cancer meeting the following&#xD;
             criteria:&#xD;
&#xD;
               -  Early-stage disease&#xD;
&#xD;
                    -  No stage IV disease&#xD;
&#xD;
               -  More than one synchronous primary breast tumor&#xD;
&#xD;
               -  Lymph node positive OR high-risk lymph node negative&#xD;
&#xD;
          -  Candidate for treatment with anthracycline- and taxane-based chemotherapy in the&#xD;
             adjuvant setting&#xD;
&#xD;
               -  Must begin therapy within 84 days after the final required surgical procedure&#xD;
&#xD;
          -  HER2/neu-negative breast cancer, defined as an immunohistochemistry (IHC) score of 0,&#xD;
             1+ or 2+ and fluorescent in situ hybridization (FISH) not amplified&#xD;
&#xD;
          -  No CNS disease (e.g., primary brain tumor or brain metastasis)&#xD;
&#xD;
          -  Hormone receptor status known&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Pre- or post-menopausal&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST or ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Urine protein:creatinine ratio ≤ 1.0&#xD;
&#xD;
          -  PT and PTT normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after&#xD;
             completion of study therapy&#xD;
&#xD;
          -  LVEF normal by MUGA scan at baseline&#xD;
&#xD;
          -  No significant bleeding within the past 6 months&#xD;
&#xD;
          -  No uncontrolled underlying bleeding diathesis&#xD;
&#xD;
          -  No nonmalignant systemic disease (e.g., cardiovascular, renal, or hepatic) that would&#xD;
             preclude study therapy, including any of the following conditions:&#xD;
&#xD;
               -  Blood pressure &gt; 150/100 mm Hg&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  New York Heart Association class II -IV congestive heart failure&#xD;
&#xD;
               -  Myocardial infarction or stroke within the past 12 months&#xD;
&#xD;
               -  Clinically significant peripheral vascular disease&#xD;
&#xD;
          -  No seizures not controlled with standard medical therapy&#xD;
&#xD;
          -  No history of stroke&#xD;
&#xD;
          -  No known allergy or hypersensitivity to study drugs (prior hypersensitivity to&#xD;
             paclitaxel allowed)&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  No serious nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within&#xD;
             the past 6 months&#xD;
&#xD;
          -  No active gastroduodenal ulcer&#xD;
&#xD;
          -  No uncontrolled intercurrent illness, including psychiatric illness or social&#xD;
             situation that would limit compliance with study requirements&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior therapy for an ipsilateral or contralateral breast cancer primary allowed&#xD;
             provided the following criteria are met:&#xD;
&#xD;
               -  No prior anthracycline therapy&#xD;
&#xD;
               -  Prior hormonal therapy for this previous breast cancer is allowed, but must be&#xD;
                  stopped during study therapy&#xD;
&#xD;
               -  At least 1 year since prior taxane therapy&#xD;
&#xD;
          -  More than 28 days since prior and no concurrent major surgery or open biopsy&#xD;
&#xD;
               -  Anticipated reconstructive surgery (e.g., tissue expander exchange) is allowed&#xD;
                  during the course of the study (bevacizumab will be held during that time as per&#xD;
                  protocol guidelines)&#xD;
&#xD;
          -  More than 7 days since prior minor surgery, including fine-needle aspiration or core&#xD;
             biopsy&#xD;
&#xD;
               -  At least 24 hours since prior indwelling catheter placement&#xD;
&#xD;
          -  No prior bevacizumab or other KDR inhibitors (e.g., VEGF Trap, semaxanib, SU6668,&#xD;
             vandetanib, vatalanib, AEE788, or IMC-1CII)&#xD;
&#xD;
          -  No concurrent full-dose anticoagulation therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy as chemoprevention&#xD;
&#xD;
          -  Concurrent participation in adjuvant hormone therapy or correlative or companion&#xD;
             (e.g., bisphosphonate clinic) studies allowed&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maura N. Dickler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>February 15, 2007</study_first_submitted>
  <study_first_submitted_qc>February 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2014</last_update_posted>
  <keyword>male breast cancer</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

